EUCTR2018-001630-18-BG招募中1 期
A randomized, parallel group, multi-center study of a fentanyl nasal spray compared with placebo nasal spray for postoperative pain management and prolonged open treatment over up to 120 hours postoperatively compared with intravenous patient-controlled analgesia using morphine - Parallel group, multi-center study of Fentanyl Nasal Spray in patients with postoperative pain
5med GmbH0 个研究点目标入组 160 人开始时间: 2023年3月2日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •[1] Male or female patients =18 years of age
- •[2] Intended stay in a Post Anesthesia Care Unit (PACU) or recovery room unit for at least 120 minutes after orthopedic surgery performed using general anesthesia for one of the following procedures:
- •- knee joint endoprosthesis surgery
- •- isolated fracture of the femur, tibia, fibula, or calcaneus, treated by open reduction and internal fixation (ORIF)
- •[3] American Society of Anesthesiology (ASA) physical status I, II, or III
- •[4] Patients who are expected to develop acute moderate or severe pain expected to require parenteral opioids for at least 24 hours after surgery
- •[5] Patients capable of handling the administration control device
- •[6] Patients willing and able (e.g. mental and physical condition) to participate in all aspects of the study as evidenced by providing signed written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 80
排除标准
- •[1] History of hypersensitivity or intolerance to the active substance or any of the excipients of the study medication
- •[2] Patients with respiratory depression, i.e. less than 10 breaths per minute
- •[3] Patients with clinically significant obstructive airways disease, which is still symptomatic under stable treatment
- •[4] Patients scheduled for post-operative analgesia supplied by a single-shot or continuous regional technique
- •[5] Patients scheduled to receive non-steroidal anti-inflammatory drugs (NSAIDs) within 12 hours before surgery, immediately after operation, and during the first 24 hours after start of treatment with study medication
- •[6] Patients scheduled to received local anesthetics in the surgical area
- •[7] Patients expected to require another surgical procedure within 48 hours post-operatively
- •[8] Patients who are expected to receive opioids other than fentanyl or sufentanil intra-operatively or fentanyl postoperatively
- •[9] Known or suspected opioid tolerance or history of opioid dependence
- •[10] Chronic treatment with opioids preoperatively on a fixed scheduled (regular) basis within 7 days before surgery
- •[11] Chronic medication with gabapentine or pregabaline
- •[12] Patients treated with medication that contains sodium oxybate
- •[13] Patients with repeated episodes of epistaxis
- •[14] Previous radiation therapy in the face area
- •[15] Intake of MAO inhibitors within the last 14 days prior to randomization
- •[16] Current anatomical abnormalities of the nose that is likely to interfere with the mucosal absorption of fentanyl via the nasal cavities
- •[17] Severe common cold, intensive hay fever or any other circumstances requiring the use of congestive nasal sprays during the study period
- •[18] Patient is currently enrolled in, or has completed less than 30 days before the screening examination of the present trial another clinical trial with an investigational drug
- •[19] Previous enrolment in this study
- •[20] Pregnant or breast-feeding women
- •[21] Women of childbearing potential unable or unwilling to use highly effective contraceptive measures until start of hospitalization. Reliable methods for women are:
- •- combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal);
- •- progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable);
- •- intrauterine device (IUD);
- •- intrauterine hormone-releasing system (IUS);
- •- bilateral tubal occlusion;
- •- vasectomized partner;
- •- sexual abstinence.
- •[22]Legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope and possible consequences of the study
- •[23]Alcohol/drug dependence or abuse (excluding tobacco abuse)
- •[24]Unreliability or lack of cooperation
- •[25]Any other condition of the patient (e.g., serious or unstable medical or psychological condition, acute psychosis) that in the opinion of the investigator may compromise evaluation of the study treatment or may jeopardize patient’s safety, compliance or adherence to protocol requirements.
研究者
相似试验
进行中（未招募）
1 期
Assess Safety and Efficacy of Vilaprisan in Subjects with Uterine FibroidseiomyomaMedDRA version: 21.1Level: LLTClassification code 10046784Term: Uterine fibroidsSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10016628Term: FibroidsSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10022794Term: Intramural leiomyoma of uterusSystem Organ Class: 100000004864EUCTR2016-002855-48-SKBayer AG766
已完成
3 期
A randomized, parallel-group, multicenter study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroidsleiomyomauterine fibroids10013326NL-OMON48550Bayer18
进行中（未招募）
1 期
Assess Safety and Efficacy of Vilaprisan in Subjects with Uterine FibroidseiomyomaMedDRA version: 20.0Level: LLTClassification code 10046784Term: Uterine fibroidsSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10016628Term: FibroidsSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10022794Term: Intramural leiomyoma of uterusSystem Organ Class: 100000004864EUCTR2016-002855-48-CZBayer AG766
进行中（未招募）
1 期
Assess Safety and Efficacy of Vilaprisan in Subjects with Uterine FibroidseiomyomaMedDRA version: 21.1Level: LLTClassification code 10046784Term: Uterine fibroidsSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10016628Term: FibroidsSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10022794Term: Intramural leiomyoma of uterusSystem Organ Class: 100000004864EUCTR2016-002855-48-DEBayer AG1,200
进行中（未招募）
1 期
Assess Safety and Efficacy of Vilaprisan in Subjects with Uterine FibroidsEUCTR2016-002855-48-NOBayer AG1,200